Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01645098 · ClinicalTrials.gov registry record · NA
Sedation During Muscle Biopsy in Patients With Duchenne Muscular Dystrophy
A NA study of Duchenne Muscular Dystrophy, sponsored by Nationwide Children's Hospital.
- Completed
- Registry status
- NA
- Development phase
- 53
- Enrollment target
- 1
- Study location
NCT01645098 is a NA study of Duchenne Muscular Dystrophy that has completed, run by Nationwide Children's Hospital. The registered enrollment target is 53 participants, below the 411-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01645098, a NA study of Duchenne Muscular Dystrophy, has completed, sponsored by Nationwide Children's Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 53 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an interventional study on Duchenne muscular dystrophy patients who will be receiving sedation for a muscle biopsy as part of another study.
Conditions Studied
Interventions
- DRUG Ketamine
- DRUG Dexmedetomidine
Study Locations (1)
Ohio
- Nationwide Children's Hospital - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2011-08 |
| Est. Completion | 2013-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01645098
The ClinicalTrials.gov registry entry for NCT01645098 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 411-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (87% lower). The listed sponsor is Nationwide Children's Hospital, which has 188 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Duchenne Muscular Dystrophy appearing as the primary indexed condition, and to 2 interventions - of which Ketamine is the first listed.
NCT01645098 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT01645098 about?
NCT01645098 is a clinical study titled "Sedation During Muscle Biopsy in Patients With Duchenne Muscular Dystrophy". This is an interventional study on Duchenne muscular dystrophy patients who will be receiving sedation for a muscle biopsy as part of another study.
What is the current status of trial NCT01645098?
This trial is currently completed. It is a NA study. The enrollment target is 53 participants. The study started on 2011-08. Estimated completion is 2013-06.
What conditions does trial NCT01645098 study?
This clinical trial studies the following conditions: Duchenne Muscular Dystrophy.
What interventions are being tested in trial NCT01645098?
The interventions under investigation include: Ketamine (DRUG), Dexmedetomidine (DRUG).
Who is sponsoring clinical trial NCT01645098?
This trial is sponsored by Nationwide Children's Hospital, which has 188 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01645098 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Duchenne Muscular Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Eplerenone for Subclinical Cardiomyopathy in Duchenne Muscular Dystrophy
COMPLETED · NA
-
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
RECRUITING · Phase 1
-
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
RECRUITING · Phase 2
-
Once Weekly Infant Corticosteroid Trial for DMD
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.